Related Experiment Video
Updated: Feb 17, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
10.3K
Variation in CYP2A6 Activity and Personalized Medicine
Julie-Anne Tanner1,2, Rachel F Tyndale3,4,5
1Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON M5T 1R8, Canada. julieanne.tanner@mail.utoronto.ca.
Journal of Personalized Medicine
|December 2, 2017
Summary
Genetic variations in the cytochrome P450 2A6 (CYP2A6) enzyme significantly impact nicotine metabolism and drug responses. Understanding CYP2A6 genetic variation is crucial for personalized medicine and smoking cessation strategies.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Enzyme Kinetics
Background:
- The cytochrome P450 2A6 (CYP2A6) enzyme plays a key role in metabolizing nicotine and numerous other therapeutic agents.
- Significant interindividual variability exists in CYP2A6 enzyme activity, influenced by genetic polymorphisms and environmental factors.
- CYP2A6 activity impacts smoking behavior, smoking cessation success, and cancer risk, making it a critical clinical consideration.
Purpose of the Study:
- To review the diverse sources of variation in CYP2A6 enzyme activity.
- To emphasize the substantial impact of CYP2A6 genetic polymorphisms on the metabolism of its substrates.
- To highlight the clinical relevance of CYP2A6 activity in personalized medicine.
Main Methods:
- Literature review of studies investigating CYP2A6 genetic polymorphisms.
- Analysis of data on CYP2A6 substrate metabolism and its clinical implications.
- Synthesis of information on non-genetic factors affecting CYP2A6 activity.
Main Results:
- The CYP2A6 gene is highly polymorphic, leading to significant differences in enzyme activity among individuals.
- CYP2A6 genetic variations affect the metabolism of nicotine, cotinine, and various drugs like efavirenz and valproic acid.
- Non-genetic factors such as drug interactions and age also modulate CYP2A6 expression and activity.
Conclusions:
- CYP2A6 genetic variation is a major determinant of individual differences in drug and nicotine metabolism.
- Understanding CYP2A6 pharmacogenetics is essential for optimizing therapeutic outcomes and managing smoking-related conditions.
- Further research into CYP2A6 modulation can lead to improved clinical interventions.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
14
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
14
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
10
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10
01:27Pharmacogenetics of Drug Metabolism: Overview
22
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
22
01:16Drug toxicity: Idiosyncratic Reactions
31
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
31
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
18
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
18
01:27Principles of Pharmacogenetics: Types of Genetic Variants
14
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
14